| acute myocardial infarction | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Azancot, 1982 | Acebutolol vs placebo | | | all cause death NaN [NaN; NaN] | | APSI, 1990 | Acebutolol vs placebo | all cause death 0.52 [0.30; 0.91] cardiovascular death 0.41 [0.22; 0.79] | | fatal and nonfatal MI 0.85 [0.36; 2.02] Sudden death 0.69 [0.25; 1.92] |
| Trial | Treatments | Patients | Method |
|---|
| Azancot, 1982 | Acebutolol (initial dose intravenously) (n=14) vs. control (n=12) | patients seen within 24 hours after the onset of uncomplicated anterior transmural myocardial infarction | open Parallel groups Sample size: 14/12 Primary endpoint: FU duration: 1 month | | APSI, 1990 | Acebutolol 200mg twice daily (n=298) vs. placebo (n=309) | patient surviving MI at hight risk | Double blind Parallel groups Sample size: 298/309 Primary endpoint: death FU duration: 318 days |
|
